BR0307919A - Sais de topiramato e composições compreendendo-os e métodos para sua fabricação e uso - Google Patents

Sais de topiramato e composições compreendendo-os e métodos para sua fabricação e uso

Info

Publication number
BR0307919A
BR0307919A BR0307919-8A BR0307919A BR0307919A BR 0307919 A BR0307919 A BR 0307919A BR 0307919 A BR0307919 A BR 0307919A BR 0307919 A BR0307919 A BR 0307919A
Authority
BR
Brazil
Prior art keywords
topiramate
crystals
salts
methods
compositions
Prior art date
Application number
BR0307919-8A
Other languages
English (en)
Inventor
Irn Almarsson
Matthew L Peterson
Julius Remenar
Original Assignee
Transform Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transform Pharmaceuticals Inc filed Critical Transform Pharmaceuticals Inc
Publication of BR0307919A publication Critical patent/BR0307919A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)

Abstract

"SAIS DE TOPIRAMATO E COMPOSIçõES COMPREENDENDO-OS E MéTODOS PARA SUA FABRICAçãO E USO". A invenção compreende sais de topiramato, e formas polimorfas, solvatos, hidratos, desidratos, co-cristais, anidras ou amorfas dele, bem como composições farmacêuticas e formas de dosagem unitária farmacêuticas contendo os mesmos. Em particular, a invenção compreende sais farmaceuticamente aceitáveis de topiramato, incluindo sem limitação topiramato de sódio, topiramato de lítio, topiramato de potássio, ou suas formas polimorfas, solvatos, hidratos, desidratos, co-cristais, anidras e amorfas deles. A invenção compreende ainda co-cristais ou complexos de topiramato, bem como composições farmacêuticas compreendendo os mesmos. A invenção também compreende métodos de tratamento ou prevenção de uma variedade de doenças e condições incluindo, mas não limitado a, ataques, condições epiléticas, tremores, distúrbios de função cerebral, obesidade, dor neuropática, distúrbios afetivos, parada de uso de tabaco, enxaquecas e cefaléia histamínica.
BR0307919-8A 2002-02-15 2003-02-14 Sais de topiramato e composições compreendendo-os e métodos para sua fabricação e uso BR0307919A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US35676402P 2002-02-15 2002-02-15
US38028802P 2002-05-15 2002-05-15
US40697402P 2002-08-30 2002-08-30
US10/232,589 US6559293B1 (en) 2002-02-15 2002-09-03 Topiramate sodium trihydrate
PCT/US2003/004357 WO2003070738A2 (en) 2002-02-15 2003-02-14 Topiramate salts and compositions comprising and methods of making and using the same

Publications (1)

Publication Number Publication Date
BR0307919A true BR0307919A (pt) 2004-12-21

Family

ID=27499652

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0307919-8A BR0307919A (pt) 2002-02-15 2003-02-14 Sais de topiramato e composições compreendendo-os e métodos para sua fabricação e uso

Country Status (13)

Country Link
US (4) US6559293B1 (pt)
EP (1) EP1485388A2 (pt)
JP (1) JP2005524645A (pt)
KR (1) KR20050002826A (pt)
CN (1) CN1646538A (pt)
AU (1) AU2003211021A1 (pt)
BR (1) BR0307919A (pt)
CA (1) CA2476422A1 (pt)
HR (1) HRP20040847A2 (pt)
IL (1) IL163549A0 (pt)
MX (1) MXPA04007968A (pt)
NO (1) NO20043819L (pt)
WO (1) WO2003070738A2 (pt)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080292700A1 (en) * 1997-04-21 2008-11-27 Biovail Laboratories Controlled release formulations using intelligent polymers
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7041650B2 (en) * 2001-07-09 2006-05-09 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivative salts
UA78211C2 (en) * 2001-07-09 2007-03-15 Ortho Mcneil Pharm Inc Salts of fructopyranose derivatives as anticonvulsant
AU2002333644A1 (en) * 2001-09-17 2003-04-01 Glaxo Group Limited Dry powder medicament formulations
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US7927613B2 (en) * 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US20100311701A1 (en) * 2002-02-15 2010-12-09 Transform Pharmaceuticals, Inc Pharmaceutical Co-Crystal Compositions
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
US20090088443A1 (en) * 2002-02-15 2009-04-02 Julius Remenar Novel crystalline forms of conazoles and methods of making and using the same
JP3951743B2 (ja) * 2002-02-28 2007-08-01 松下電器産業株式会社 半導体装置およびその製造方法
CA2477923C (en) * 2002-03-01 2021-02-23 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20070059356A1 (en) * 2002-05-31 2007-03-15 Almarsson Oern Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
US7939102B2 (en) * 2002-06-07 2011-05-10 Torrent Pharmaceuticals Ltd. Controlled release formulation of lamotrigine
MXPA05000232A (es) * 2002-06-21 2005-06-17 Transform Pharmaceuticals Inc Composiciones farmaceuticas con disolucion mejorada.
AR039744A1 (es) * 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
CA2494233A1 (en) * 2002-07-29 2004-02-05 Alza Corporation Formulations and dosage forms for controlled delivery of topiramate
JP4630665B2 (ja) * 2002-09-13 2011-02-09 モタック・ニューロサイエンス・リミテッド ２，３−ベンゾジアゼピンによる基底核関連運動障害の治療
WO2004026299A1 (en) * 2002-09-17 2004-04-01 Motac Neuroscience Limited Treatment of dyskinesia
US8183290B2 (en) * 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US6949518B1 (en) * 2003-06-25 2005-09-27 Pao-Hsien Chu Methods for treating macular degeneration with topiramate
US20060210485A1 (en) * 2003-07-11 2006-09-21 Marian Thomas Pharmaceutical formulations
US20050058707A1 (en) * 2003-08-06 2005-03-17 Iran Reyes Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
JP2007503389A (ja) * 2003-08-22 2007-02-22 アルザ・コーポレーシヨン 長期間にわたるトピラメートの段階的送達
CA2564227A1 (en) * 2003-09-02 2005-03-10 Alza Corporation Novel drug compositions and dosage forms of topiramate
GB0324918D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
TW200528144A (en) * 2003-11-14 2005-09-01 Alza Corp Controlled release of topiramate in liquid dosage forms
CA2550699A1 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc. Novel drug compositions and dosage forms of topiramate
EP1701706A2 (en) * 2003-12-29 2006-09-20 Alza Corporation Novel drug compositions and dosage forms
US20050175696A1 (en) * 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
TW200612905A (en) * 2004-06-16 2006-05-01 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
MY147767A (en) * 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
WO2006007448A2 (en) * 2004-06-17 2006-01-19 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions and related methods of use
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
WO2006007323A2 (en) * 2004-06-28 2006-01-19 Alza Corporation Dosage forms for low solubility and/or low dissolution rate free acid pharmaceutical agents
CN1988889A (zh) * 2004-07-22 2007-06-27 株式会社太平洋 含托吡酯的缓释制剂及其制备方法
ATE400565T1 (de) * 2004-08-24 2008-07-15 Janssen Pharmaceutica Nv Als antikonvulsive mittel geeignete neue benzokondensierte heteroarylsulfamidderivate
WO2006047291A2 (en) * 2004-10-21 2006-05-04 Advanced Neuromodulation Systems, Inc. Spinal cord stimulation to treat auditory dysfunction
US8779175B2 (en) * 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
US7638291B2 (en) * 2004-10-25 2009-12-29 Seradyn, Inc. Immunoassays for topiramate
US20060088886A1 (en) * 2004-10-25 2006-04-27 Anlong Ouyang Topiramate analogs
US20060233892A1 (en) * 2005-04-19 2006-10-19 Curt Hendrix Topiramate compositions for treatment of headache
US20110117070A1 (en) * 2005-04-19 2011-05-19 Aurora Sheena K Compositions and methods for treating headache
AU2006249577A1 (en) * 2005-05-20 2006-11-30 Janssen Pharmaceutica N.V. Process for preparation of sulfamide derivatives
EP1888030A1 (en) * 2005-05-25 2008-02-20 Janssen Pharmaceutica N.V. Pediatric formulation of topiramate
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
WO2007038524A2 (en) * 2005-09-28 2007-04-05 Ssci, Inc. Cocrystallization methods
US20070155827A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
US8497298B2 (en) * 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8716231B2 (en) * 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8691867B2 (en) * 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8937096B2 (en) * 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
AR058389A1 (es) * 2005-12-19 2008-01-30 Janssen Pharmaceutica Nv Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
US20070155823A1 (en) * 2005-12-19 2007-07-05 Smith-Swintosky Virginia L Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
TW200812573A (en) * 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
KR20150003925A (ko) * 2006-06-15 2015-01-09 유씨비 파르마 게엠베하 상승적 항경련 효과를 갖는 약제학적 조성물
WO2008027557A2 (en) * 2006-08-31 2008-03-06 Spherics, Inc. Topiramate compositions and methods of enhancing its bioavailability
US20090239942A1 (en) * 2006-09-15 2009-09-24 Cloyd James C Topiramate Compositions and Methods of Making and Using the Same
SI2061458T1 (sl) * 2006-09-15 2015-04-30 Regents Of The University Of Minnesota Sestavki topiramata in metode za njihovo uporabo
JP2010505811A (ja) 2006-10-04 2010-02-25 ファイザー・プロダクツ・インク カルシウム受容体アンタゴニストとしてのピリド［４，３−ｄ］ピリミジン−４（３Ｈ）−オン誘導体
JP5489719B2 (ja) 2006-11-17 2014-05-14 スパーナス ファーマシューティカルズ インコーポレイテッド トピラマートの徐放性配合物
MX2009003911A (es) * 2006-12-04 2009-05-28 Supernus Pharmaceuticals Inc Formulaciones de liberacion inmediata, mejoradas de topiramato.
CN100432087C (zh) * 2007-04-26 2008-11-12 杭州盛美医药科技开发有限公司 一种托吡酯的制备方法
US7751907B2 (en) 2007-05-24 2010-07-06 Smiths Medical Asd, Inc. Expert system for insulin pump therapy
ATE526969T1 (de) * 2007-07-17 2011-10-15 Meddev Inc Behandlung von depressionen und depressiven stimmungen
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
US20110251468A1 (en) * 2010-04-07 2011-10-13 Ivan Osorio Responsiveness testing of a patient having brain state changes
US20090247616A1 (en) * 2008-03-26 2009-10-01 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of anxiety
US20090247617A1 (en) * 2008-03-26 2009-10-01 Abdel-Magid Ahmed F Process for the preparation of benzo-fused heteroaryl sulfamates
US8222218B2 (en) * 2008-03-27 2012-07-17 Seton Hall University Cyclopropanated carbohydrates
US20090304789A1 (en) * 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
BRPI0915890A2 (pt) 2008-06-23 2015-11-03 Janssen Pharmaceutica Nv forma cristalina de (2s)-(-)-n-(6-cloro-2,3-di-hidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida
US8815939B2 (en) * 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
CA2737461A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
BRPI0914454A2 (pt) * 2008-10-21 2015-10-27 Novodermix Internat Ltd "composição para o tratamento do tecido epitelial"
EP3284494A1 (en) 2009-07-30 2018-02-21 Tandem Diabetes Care, Inc. Portable infusion pump system
JP6055076B2 (ja) * 2012-03-23 2016-12-27 インスティテュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシズ ピー．エル．エー．チャイナ シネフリン及びトピラマートを含む組み合わせ製品
CN103316026B (zh) 2012-03-23 2016-05-11 中国人民解放军军事医学科学院毒物药物研究所 含芬特明和托吡酯的联合产品及其制备方法
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
US9555186B2 (en) 2012-06-05 2017-01-31 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2014167439A1 (en) 2013-03-26 2014-10-16 Wockhardt Limited Modified release pharmaceutical compositions of topiramate or salts thereof
CN103304483A (zh) * 2013-05-23 2013-09-18 江汉大学 N-3-芳胺-5-环丙烷螺环乙内酰脲及其制备方法和应用
GB201311984D0 (en) * 2013-07-04 2013-08-21 Univ Cardiff Methods and compounds for preventing or treating osteoarthritis
ES2813450T3 (es) * 2013-08-19 2021-03-23 Univ California Compuestos y métodos para tratar un trastorno epiléptico
EA201992474A3 (ru) 2015-02-25 2020-05-31 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорниа Агонисты 5ht для лечения нарушений
US10278948B1 (en) * 2015-09-03 2019-05-07 Tian Xia Method for transnasal delivery of anticonvulsant and therapeutic treatments
RU2747316C2 (ru) 2016-03-01 2021-05-04 Асцендис Фарма Боун Дизизис А/С Пролекарства pth
JP7085535B2 (ja) 2016-09-29 2022-06-16 アセンディス ファーマ ボーン ディジージズ エー／エス ピーク対トラフ比が小さいｐｔｈ化合物
EP4275677A3 (en) 2016-09-29 2024-01-10 Ascendis Pharma Bone Diseases A/S Dosage regimen for a controlled-release pth compound
EP3883546A1 (en) 2018-11-21 2021-09-29 Rosemont Pharmaceuticals Ltd Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability
MA55726A (fr) * 2019-04-18 2022-02-23 Prevep Llc Associations thérapeutiques, compositions pharmaceutiques liquides, kits pour leur préparation et leurs méthodes d'utilisation
US20210169844A1 (en) 2019-12-10 2021-06-10 Tulex Pharmaceuticals Inc. Compositions and methods for treating epilepsy, seizures and other conditions

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5242942A (en) 1992-04-28 1993-09-07 Mcneilab, Inc. Anticonvulsant fructopyranose cyclic sulfites and sulfates
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5498629A (en) * 1993-12-23 1996-03-12 Ortho Pharmaceutical Corporation Anticonvulsant pseudofructopyranose sulfamates
AU2452495A (en) * 1994-05-18 1995-12-05 Zeneca Limited Disazo compound
US5998380A (en) 1995-10-13 1999-12-07 New England Medical Center Hospitals, Inc. Treatment of migraine
US5952187A (en) * 1995-12-01 1999-09-14 Oxis International, Inc. Topiramate immunoassay
ATE224189T1 (de) 1996-06-28 2002-10-15 Ortho Mcneil Pharm Inc Antikonvulsive sulfamatderivate zur behandlung von fettleibigkeit
US5753693A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
EP1052224B2 (en) 1996-08-30 2014-02-12 Showa Denko K.K. Particles, aqueous dispersion and film of titanium oxide, and preparation thereof
US5935933A (en) 1997-07-16 1999-08-10 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating neuropathic pain
US5760007A (en) 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
US6890951B2 (en) 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
US6541520B1 (en) 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
AU1238500A (en) * 1998-11-02 2000-05-22 Alza Corporation Controlled delivery of active agents
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
DE60015070T2 (de) 1999-01-19 2006-01-05 Ortho-Mcneil Pharmaceutical, Inc. Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
DK1158973T3 (da) 1999-02-24 2005-05-30 Univ Cincinnati Anvendelse af sulfamatderivater til behandling af impulskontrolafvigelser
WO2000061136A1 (en) 1999-04-08 2000-10-19 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in lowering blood pressure
US6486198B1 (en) 1999-05-28 2002-11-26 Jeffrey Berlant Compounds and methods for the treatment of post traumatic stress disorder
US6488962B1 (en) * 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US6191117B1 (en) 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
US6455666B1 (en) * 2000-10-11 2002-09-24 Daicel Chemical Industries, Ltd. Polyesters and production process thereof
UA78211C2 (en) * 2001-07-09 2007-03-15 Ortho Mcneil Pharm Inc Salts of fructopyranose derivatives as anticonvulsant
US20030072802A1 (en) 2001-10-11 2003-04-17 R.T. Alamo Ventures, Inc. Sustained release topiramate
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate

Also Published As

Publication number Publication date
WO2003070738A2 (en) 2003-08-28
IL163549A0 (en) 2005-12-18
US20040053853A1 (en) 2004-03-18
US20050169982A1 (en) 2005-08-04
NO20043819L (no) 2004-09-13
WO2003070738A3 (en) 2003-09-25
MXPA04007968A (es) 2005-10-18
US6699840B2 (en) 2004-03-02
JP2005524645A (ja) 2005-08-18
US20030166581A1 (en) 2003-09-04
CA2476422A1 (en) 2003-08-28
EP1485388A2 (en) 2004-12-15
AU2003211021A1 (en) 2003-09-09
US6559293B1 (en) 2003-05-06
US7351695B2 (en) 2008-04-01
HRP20040847A2 (en) 2005-06-30
CN1646538A (zh) 2005-07-27
KR20050002826A (ko) 2005-01-10

Similar Documents

Publication Publication Date Title
BR0307919A (pt) Sais de topiramato e composições compreendendo-os e métodos para sua fabricação e uso
ATE323705T1 (de) Substituierte indolizinähnliche verbindungen und ihre verwendung
NO20060278L (no) Piperazinderivater og fremgangsmater for anvendelse
PT1326613E (pt) Utilizacao de derivados de imidazo[1,2-a]piridin-,imidazo[1,2-a]pirimidin- e imidazo[1,2-a]pirazin-3-il-amina substituidos para a fabricacao de medicamentos para inibicao de nos
MXPA04005444A (es) Ureas de 2-aminobenzotiazoles como moduladores de adenosina.
ES2156162T3 (es) Compuestos activos en un nuevo sitio sobre canales del calcio accionados por un receptor, utiles para el tratamiento de trastornos y enfermedades neurologicas.
BR0311494A (pt) Novos indóis substituìdos
DE60318193D1 (en) Phenethanolaminderivate
DK1651615T3 (da) Pyridazinyl-piperaziner og anvendelse deraf som histamin-H3-receptorligander
PT2150530E (pt) Derivados de sulfonamida substituídos
MXPA05010883A (es) Derivados de amina ciclica y su uso en el tratamiento de trastornos inflamatorios relacionados mediados por bradiquinina.
TW200504034A (en) Therapeutic agents
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
NO20063308L (no) Kombinasjon av flupirtin og tramadol
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
SE0400184D0 (sv) New therapeutical use
BRPI0408689B8 (pt) derivados de benzenosulfonamida, método para preparação e utilização disso para o tratamento da dor
MEP42908A (en) Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use of the same as medicaments, and medicament containing such compounds
ATE296098T1 (de) Verwendung von topiramat zur behandlung und diagnostizierung von atemstörungen während des schlafens und mittel zur durchführung der behandlung und diagnose
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
EA200600854A1 (ru) Новые соли тиотропия, способ их получения, а также содержащие их лекарственные композиции
EA200700807A1 (ru) Новые циклические и ациклические пропеноны для лечения заболеваний цнс
ATE371724T1 (de) Behandlung neurodegenerativer krankheiten
UY28993A1 (es) Tetrahidroisoquinolinas sustituidas en calidad de inhibidores de mpm, procedimiento para su uso como medicamento.-
BR0105787A (pt) Composição farmacêutica, uso de um composto farmacêutico, método para tratamento de distúrbios, composto farmacêutico e método para confeccionar um composto farmacêutico

Legal Events

Date Code Title Description
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]